US Diabetes Drugs Market Analysis

US Diabetes Drugs Market Analysis


$ 3999

The US diabetes drugs market size was valued at $25.94 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 4.1% from 2022 to 2030 and will reach $35.78 Bn in 2030. The market is segmented by drug type, application, and distribution channel. The US diabetes drug market will grow because the prevalence of diabetes in the US is a major driver of the market. There is a large and growing demand for diabetes medications, including insulin and oral medications, to manage the disease and prevent its complications. The key market players are Johnson & Johnson, Novo Nordisk, Novartis, Merck, Eli Lilly and Company, and others.

ID: IN10USPH009 CATEGORY: Pharmaceuticals GEOGRAPHY: US AUTHOR: Chandani Patel

Buy Now

US Diabetes Drugs Market Executive Summary

The US diabetes drugs market size was valued at $25.94 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 4.1% from 2022 to 2030 and will reach $35.78 Bn in 2030. The United States has one of the highest health expenditures in the world, both in absolute terms and as a percentage of its gross domestic product (GDP). According to data from the Centers for Medicare and Medicaid Services (CMS), US healthcare spending totaled $3.8 trillion in 2019 or $11,582 per person. This represented approximately 17.7% of the US GDP.

There are several factors that contribute to high health expenditures in the US. One of the biggest drivers is the high cost of medical services and treatments. The US has some of the highest healthcare prices in the world, including prescription drugs, medical devices, and hospital care. Additionally, the US has a higher prevalence of chronic diseases, such as diabetes, heart disease, and obesity, which require ongoing medical treatment and management.

Diabetes is a significant public health issue in the United States, affecting Mns of people and placing a significant burden on the healthcare system. According to the Centers for Disease Control and Prevention (CDC), in 2020, approximately 34.2 Mn people in the US, or 10.5% of the population, had diabetes. This includes both diagnosed and undiagnosed cases. The incidence of diabetes, or the rate at which new cases of the disease are diagnosed, has also been increasing in recent years. According to the CDC, in 2018, there were approximately 1.5 Mn new cases of diabetes diagnosed in the US.

The high prevalence and incidence of diabetes in the US has a significant impact on the diabetes drugs market. There is a large and growing demand for diabetes medications, including insulin and oral medications, to manage the disease and prevent its complications. In 2019, the global diabetes drugs market was valued at $65.4 Bn, and the US was the largest market for diabetes drugs, accounting for a significant share of the market.

The demand for diabetes medications has led to a highly competitive and innovative diabetes drug market in the US. There are numerous pharmaceutical companies that produce diabetes drugs, ranging from large multinational corporations to smaller specialty companies. The market includes both branded and generic drugs, and there is a significant investment in research and development to develop new and more effective treatments for diabetes.

us diabetes drugs market

Market Dynamics

Market Growth Drivers

  1. High prevalence of diabetes: The prevalence of diabetes in the US is a major driver of the market. There is a large and growing demand for diabetes medications, including insulin and oral medications, to manage the disease and prevent its complications.
  2. Ongoing need for treatment and management: Diabetes is a chronic disease that requires ongoing treatment and management, which creates a sustained demand for diabetes medications.
  3. Advances in diabetes drug research and development: There is a significant investment in research and development to develop new and more effective treatments for diabetes, which has led to the development of new classes of diabetes medications.
  4. Increasing awareness and education: Increased awareness and education about diabetes and its complications has led to greater demand for diabetes medications and improved treatment and management of the disease.

Market Restraints

  1. High cost of diabetes medications: The high cost of diabetes medications, including insulin, is a significant barrier to access and affordability for many people with diabetes.
  2. Regulatory issues: The approval process for new diabetes medications can be lengthy and expensive, which can slow down innovation and limit competition in the market.
  3. Competition from alternative therapies: Alternative therapies, such as lifestyle modifications and non-pharmacological interventions, can also be effective in managing diabetes, which can limit demand for diabetes medications.
  4. Patent expirations: The expiration of patents for some diabetes medications can result in increased competition from generic drugs, which can reduce revenue for pharmaceutical companies.

Competitive Landscape

Key Players

  • Johnson & Johnson
  • Bayer Pharmaceuticals
  • Novo Nordisk
  • Sanofi
  • Merck
  • Eli Lilly and Company
  • AstraZeneca
  • Takeda Pharmaceutical Company Limited
  • Biocon ltd
  • Bristol-Myers Squibb
  • Boehringer Ingelheim
  • Novartis
  • GlaxoSmithKline
  • Lupin ltd
  • Piramal healthcare ltd
  • Ranbaxy laboratories ltd.

Recent Developments

In 2021, the US FDA approved several new drugs for the treatment of diabetes. These include Zegalogue, a new formulation of glucagon for the treatment of severe hypoglycemia, and Wegovy, a once-weekly injection for the treatment of type 2 diabetes and obesity.

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario

The development and approval of diabetes drugs in the United States is regulated by the US Food and Drug Administration (FDA). The FDA is responsible for ensuring that drugs are safe and effective for their intended use, and that they meet certain standards of quality.

Before a new diabetes drug can be approved for use in the US, it must go through a rigorous testing and approval process. This process typically involves three phases of clinical trials, in which the drug is tested for safety and efficacy in human subjects. The FDA reviews the results of these clinical trials and other data to determine whether to approve the drug for use. Once a diabetes drug is approved by the FDA, it can be marketed and sold in the US. However, the FDA continues to monitor the drug's safety and efficacy after it is approved, and can take action to withdraw or restrict the drug if new safety concerns arise.

In addition to the FDA's regulatory oversight, there are also regulations governing the marketing and promotion of diabetes drugs in the US. Pharmaceutical companies must follow certain guidelines and restrictions when advertising their products to healthcare providers and consumers. There are also regulations governing the import and export of diabetes drugs in the US, which are designed to ensure that drugs are safe and of high quality. These regulations include requirements for labeling and packaging, as well as for testing and inspection of imported drugs.

In the US, reimbursement for diabetes drugs is primarily provided through health insurance plans, including private insurance, Medicare, and Medicaid. The reimbursement process can be complex, and can depend on factors such as the patient's insurance coverage, the specific diabetes drug being prescribed, and the prescribing physician's practice.

One of the key factors that affects reimbursement for diabetes drugs is the patient's insurance coverage. Many health insurance plans require patients to pay a portion of the cost of their medications, either through co-payments or deductibles. The amount of the patient's out-of-pocket expenses can vary depending on the specific insurance plan, as well as the drug being prescribed. Medicare, the federal health insurance program for people over 65 and certain individuals with disabilities, provides coverage for diabetes drugs for eligible beneficiaries. Medicare coverage for diabetes drugs can depend on the specific drug being prescribed, as well as the patient's insurance plan.

Medicaid, the joint federal-state program that provides health coverage for low-income individuals, also provides coverage for diabetes drugs. Medicaid coverage for diabetes drugs can vary depending on the specific drug being prescribed, as well as the state in which the patient resides. In addition to insurance coverage, there are also programs that provide financial assistance to patients who need help paying for their diabetes medications. For example, some pharmaceutical companies offer patient assistance programs that provide free or discounted medications to eligible patients.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Diabetes Drugs Market Segmentation

By Drug Type (Revenue, USD Bn):

The drug types considered, in this report include Injectable Drugs and Oral Drugs. Injectable drugs are further classified into insulin-based and non-insulin-based injectables. Oral drugs are further classified into various classes as per their mechanism of action as mentioned below :

  • Injectable Drugs
    • Insulin Based Injectables
    • Non-insulin Based Injectables
      • Exenatide (Byetta)
      • Dulaglutide (Trulicity)
      • Semaglutide (Ozempic, Wegovy)
      • Liraglutide (`Saxenda, Victoza)
      • Lixisenatide (Adlyxin)
      • Pramlintide (Symlin)
      • Tirzepatide (Mounjaro)
      • Albiglutide (Tanzeum)
  • Oral Drugs
    • Biguanides - Metformin (Glucophage and Glucophase XR)
    • Sulfonylureas - Glimepiride (Amaryl), Glyburide (DiaBeta), Glipizide (Glucotrol), Gliclazide (Diamicron), Chlorpropamide (Diabinese)
    • Meglitinides and D-Phenylalanine Derivatives - Repaglinide (Prandin), Nateglinide (Starlix)
    • Thiazolidinediones (TZDs) - Rosiglitazone (Avandia), Pioglitazone (Actos)
    • Dipeptidyl peptidase-IV (DPP-4) inhibitors - Sitagliptin (Januvia), Saxagliptin (Onglyza), Linagliptin (Tradjenta), and Alogliptin (Nesina and Vipidia), Teneligliptin (Tenelia), Vildagliptin (Galvus)
    • Alpha-glucosidase Inhibitors - Acarbose (Precose), Miglitol (Glyset), Voglibose (Voglib)
    • Sodium-glucose co-transporter-2 (SGLT2) inhibitors - Canagliflozin (Invokana), Dapagliflozin (Farxiga), Empagliflozin (Jardiance), Ertugliflozin (Stelgatro)
    • Dopamine D2 agonist – Bromocriptine (Parlodel and Cycloset)
    • Glucagon like peptide 1 (GLP-1) receptor agonists - Semaglutide (Rybelsus)
    • Bile Acid Sequestrants (BASs) - Colesevelam (Welchol)
    • Others (Fixed Dose Combination Drugs)

By Application (Revenue, USD Bn):

Based on application, the market is segmented into Type 1 and Type 2. The 2 types of diabetes drugs are segmented and dominate the market. The Type 2 diabetes segment accounts for the largest sales of the worldwide market a few different kinds. The excessive prevalence of type 2 because of sedentary lifestyles and obesity in all age groups is attributed to the current situation. Around 10% of all diabetes cases are type 1, and approximately 90% of all cases of diabetes in UK are type 2. Hence, it is estimated to the diabetes drugs market will grow across the globe during the forecast period.

  • Type 1 diabetes (due to β-cell destruction, usually leading to absolute insulin deficiency)
  • Type 2 diabetes (due to a progressive insulin secretory defect on the background of insulin resistance)
  • Other diabetes types

By Distribution Channel (Revenue, USD Bn):

Based on distribution channels, the market is classified into hospital pharmacies, rental pharmacies, and online pharmacies. The hospital pharmacies captured the highest market share, owing to the availability of trained & qualified personnel and favorable reimbursement structure. Online pharmacies are estimated to register the highest CAGR in the forecast period, it is attributed to the technological adaptation and acceptance of online pharmacies. Retail pharmacies showed a moderate market share improvement in the healthcare facilities in developing countries is anticipated to propel the popularity of retail pharmacies during the forecast period.

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Insights10 will provide you with the reports within 10 key parameters which are:

  1. Market Overview
  2. Market Growth Drivers & Restraints
  3. Epidemiology of Disease Type
  4. Market Segmentation
  5. Market Share
  6. Competitive Landscape
  7. Key Company Profiles
  8. Healthcare Policies & Regulatory Framework
  9. Reimbursement Scenario
  10. Factors Driving Future Growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.

 

Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:

 

 

Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and  Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.

We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.

 

 

Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)

  • Establishing market drivers and trends
  • Analyzing the regulatory landscape to understand future growth
  • Market Segment based analysis to obtain revenue/volume
  • ​Analyzing current needs and determining penetration to estimate the market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.

Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.

The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


This report addresses

  • Intelligent insights to take informed business decisions
  • Qualitative, acute and result oriented market analysis
  • Market size and forecasts from 2022 to 2030
  • Opportunities for expansion and in-depth market analysis
  • Segmentation and regional revenue forecasts
  • Analysis of the market share and competitive landscape
  • Strategic Recommendations to chart future course of action
  • Comprehensive Market Research Report in PDF and PPT formats

Need more?

  • Ask our analyst how this study was put together to learn more
  • Discuss additional requirements as part of the free customisation
  • Add more countries or regions to the scope 
  • Get answers to specific business questions 
  • Develop the business case to launch the product
  • Find out how this report may influence your business revenue
Last updated on: 30 October 2023
Updated by: Vidhi Upadhyay

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up